The Eosinophilic Esophagitis drugs in development market research report provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Eosinophilic Esophagitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued products.
GlobalData tracks 37 drugs in development for Eosinophilic Esophagitis by 35 companies/universities/institutes. The top development phase for Eosinophilic Esophagitis is preclinical with 11 drugs in that stage. The Eosinophilic Esophagitis pipeline has 37 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Eosinophilic Esophagitis pipeline products market are: Delta 4, NImmune Biopharma and HBC Immunology.
The key targets in the Eosinophilic Esophagitis pipeline products market include Glucocorticoid Receptor, Interleukin 4 Receptor Subunit Alpha, and Interleukin 15.
The key mechanisms of action in the Eosinophilic Esophagitis pipeline product include Glucocorticoid Receptor Agonist with three drugs in Phase III. The Eosinophilic Esophagitis pipeline products include nine routes of administration with the top ROA being Oral and seven key molecule types in the Eosinophilic Esophagitis pipeline products market including Small Molecule, and Monoclonal Antibody.
Eosinophilic Esophagitis overview
Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil, that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting; coughing; heartburn; and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity, and alcohol or cigarette use. Treatment includes antivirals, antifungals, and pain relievers.
For a complete picture of Eosinophilic Esophagitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
